1
|
Li G, Chen N, Feng Z, Buller RML, Osborne J, Harms T, Damon I, Upton C, Esteban DJ. Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication. Virol J 2006; 3:88. [PMID: 17062162 PMCID: PMC1635044 DOI: 10.1186/1743-422x-3-88] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2006] [Accepted: 10/25/2006] [Indexed: 11/24/2022] Open
Abstract
Background Vaccinia virus (VACV)-DUKE was isolated from a lesion on a 54 year old female who presented to a doctor at the Duke University Medical Center. She was diagnosed with progressive vaccinia and treated with vaccinia immune globulin. The availability of the VACV-DUKE genome sequence permits a first time genomic comparison of a VACV isolate associated with a smallpox vaccine complication with the sequence of culture-derived clonal isolates of the Dryvax vaccine. Results This study showed that VACV-DUKE is most similar to VACV-ACAM2000 and CLONE3, two VACV clones isolated from the Dryvax® vaccine stock confirming VACV-DUKE as an isolate from Dryvax®. However, VACV-DUKE is unique because it is, to date, the only Dryvax® clone isolated from a patient experiencing a vaccine-associated complication. The 199,960 bp VACV-DUKE genome encodes 225 open reading frames, including 178 intact genes and 47 gene fragments. Between VACV-DUKE and the other Dryvax® isolates, the major genomic differences are in fragmentation of the ankyrin-like, and kelch-like genes, presence of a full-length Interferon-α/β receptor gene, and the absence of a duplication of 12 ORFs in the inverted terminal repeat. Excluding this region, the DNA sequence of VACV-DUKE differs from the other two Dryvax® isolates by less than 0.4%. DNA sequencing also indicated that there was little heterogeneity in the sample, supporting the hypothesis that virus from an individual lesion is clonal in origin despite the fact that the vaccine is a mixed population. Conclusion Virus in lesions that result from progressive vaccinia following vaccination with Dryvax are likely clonal in origin. The genomic sequence of VACV-DUKE is overall very similar to that of Dryvax® cell culture-derived clonal isolates. Furthermore, with the sequences of multiple clones from Dryvax® we can begin to appreciate the diversity of the viral population in the smallpox vaccine.
Collapse
Affiliation(s)
- Guiyun Li
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada
| | - Nanhai Chen
- Department of Molecular Microbiology and Immunology, St. Louis University, St. Louis, USA
| | - Zehua Feng
- Department of Molecular Microbiology and Immunology, St. Louis University, St. Louis, USA
| | - R Mark L Buller
- Department of Molecular Microbiology and Immunology, St. Louis University, St. Louis, USA
| | - John Osborne
- Centers for Disease Control and Prevention, National Center for Infectious Diseases, Atlanta, USA
| | - Tiara Harms
- Centers for Disease Control and Prevention, National Center for Infectious Diseases, Atlanta, USA
| | - Inger Damon
- Centers for Disease Control and Prevention, National Center for Infectious Diseases, Atlanta, USA
| | - Chris Upton
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada
| | - David J Esteban
- Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada
| |
Collapse
|
3
|
Knight SJL, Lese CM, Precht KS, Kuc J, Ning Y, Lucas S, Regan R, Brenan M, Nicod A, Lawrie NM, Cardy DLN, Nguyen H, Hudson TJ, Riethman HC, Ledbetter DH, Flint J. An optimized set of human telomere clones for studying telomere integrity and architecture. Am J Hum Genet 2000; 67:320-32. [PMID: 10869233 PMCID: PMC1287181 DOI: 10.1086/302998] [Citation(s) in RCA: 235] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2000] [Accepted: 05/22/2000] [Indexed: 11/04/2022] Open
Abstract
Telomere-specific clones are a valuable resource for the characterization of chromosomal rearrangements. We previously reported a first-generation set of human telomere probes consisting of 34 genomic clones, which were a known distance from the end of the chromosome ( approximately 300 kb), and 7 clones corresponding to the most distal markers on the integrated genetic/physical map (1p, 5p, 6p, 9p, 12p, 15q, and 20q). Subsequently, this resource has been optimized and completed: the size of the genomic clones has been expanded to a target size of 100-200 kb, which is optimal for use in genome-scanning methodologies, and additional probes for the remaining seven telomeres have been identified. For each clone we give an associated mapped sequence-tagged site and provide distances from the telomere estimated using a combination of fiberFISH, interphase FISH, sequence analysis, and radiation-hybrid mapping. This updated set of telomeric clones is an invaluable resource for clinical diagnosis and represents an important contribution to genetic and physical mapping efforts aimed at telomeric regions.
Collapse
Affiliation(s)
- Samantha J. L. Knight
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Christa M. Lese
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Kathrin S. Precht
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Julie Kuc
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Yi Ning
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Sarah Lucas
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Regina Regan
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Mary Brenan
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Alison Nicod
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - N. Martin Lawrie
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Donald L. N. Cardy
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Huy Nguyen
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Thomas J. Hudson
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Harold C. Riethman
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - David H. Ledbetter
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| | - Jonathan Flint
- Institute of Molecular Medicine, John Radcliffe Hospital, Oxford; Department of Human Genetics, The University of Chicago, Chicago; Gene-Care Medical Genetics Center and George Washington University, Washington, DC; Cytocell Ltd., Adderbury, Oxfordshire, United Kingdom; Center for Genome Research, Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA; Montreal Genome Centre, McGill University Health Centre, Montreal; and The Wistar Institute, Philadelphia
| |
Collapse
|